Cencora, Inc. (COR)
| Market Cap | 59.56B +3.6% |
| Revenue (ttm) | 328.68B +5.9% |
| Net Income | 2.55B +50.5% |
| EPS | 13.05 +52.0% |
| Shares Out | 194.56M |
| PE Ratio | 23.45 |
| Forward PE | 16.46 |
| Dividend | $2.40 (0.78%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 1,353,843 |
| Open | 305.00 |
| Previous Close | 303.44 |
| Day's Range | 303.30 - 308.84 |
| 52-Week Range | 244.82 - 377.54 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 353.50 (+15.47%) |
| Earnings Date | Aug 5, 2026 |
About COR
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, ... [Read more]
Financial Performance
In fiscal year 2025, Cencora's revenue was $321.33 billion, an increase of 9.31% compared to the previous year's $293.96 billion. Earnings were $1.55 billion, an increase of 2.99%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for COR stock is "Buy." The 12-month stock price target is $353.5, which is an increase of 15.47% from the latest price.
News
Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2026 on Wednesday, August 5, 2026, prior to the openi...
Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced a multi-site pilot of its enhanced Nucleus® inventory management solution, designed to help spec...
Suncrete, Inc. Completes Arkansas Acquisition
Company Enhances Scale and Expands Footprint into New Markets TULSA, Okla., June 15, 2026 /PRNewswire/ -- Suncrete, Inc. (Nasdaq: RMIX) ("Suncrete" or the "Company"), a ready-mix concrete logistics an...
Cencora Announces Samantha Hammock as Chief Human Resources Officer
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer (CHRO), has announced she will retire f...
Cencora to Support U.S. Distribution of Kite's CAR T-Cell Therapies
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite's U.S. Food and Drug Administration (FDA)-approved CAR T-cell ...
Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, ...
Cencora revises forecast for 2026, approves $2 billion share buyback
U.S. drug distributor Cencora on Thursday raised the lower end of its fiscal 2026 earnings forecast citing recent share repurchases, and also approved a new $2 billion stock buyback plan.
Cencora Announces Updated Fiscal Year 2026 Financial Outlook
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted ...
Cencora Transcript: Bank of America Global Healthcare Conference 2026
Management reaffirmed confidence in full-year and long-term guidance, with EPS expected at $17.65–$17.90 and $1 billion in share repurchases planned. U.S. Healthcare Solutions growth is set to accelerate, M&A integration is progressing well, and AI-driven efficiency initiatives are underway.
Cencora Earnings Call Transcript: Q2 2026
Adjusted EPS grew 7.5% and operating income rose in both core segments, despite revenue headwinds from price reductions, customer losses, and faster biosimilar conversions. Full-year EPS guidance was raised, with strong cash flow and resumed share buybacks supporting long-term growth.
Cencora Earnings release: Q2 2026
Cencora released its Q2 2026 earnings on May 6, 2026, summarizing the period's financial results.
Cencora Slides: Q2 2026
Cencora has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 6, 2026.
Cencora Quarterly report: Q2 2026
Cencora has published its Q2 2026 quarterly earnings report on May 6, 2026.
Cencora raises annual profit forecast despite quarterly miss
Cencora reported second-quarter results below Wall Street estimates on Wednesday but raised its annual profit forecast, betting on a steady demand for specialty medicines.
Cencora Reports Fiscal 2026 Second Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 second quarter ended March 31, 2026, revenue increased 3.8 percent year-over-year to $78.4 billion. ...
CareMetx Acquires U.S.-based Patient Services and Free Goods Pharmacy Operations from Cencora, Significantly Expanding Its Patient Access Platform
As demand for technology-forward patient services accelerates, combined organization positions CareMetx to deliver greater innovation for biopharma clients. As demand for technology-forward patient se...
Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening...
Cencora to buy retina business of EyeSouth Partners for $1.1 billion
Drug distributor Cencora said on Monday it would buy the retina business of eye care network EyeSouth Partners for $1.1 billion, expanding its eye care unit.
Cencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners' Retina Business
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the signing of a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. Upon completion of t...
Cencora Announces Financial Leadership Transition
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora ...
Cencora Transcript: Leerink Global Healthcare Conference 2026
Strong U.S. segment growth and expanded MSO capabilities drove increased guidance, while strategic acquisitions and divestitures enhanced operational focus. Specialty and generics markets remain healthy, with ongoing investments in synergies, contracting, and customer relationships supporting long-term growth.
Cencora Transcript: Barclays 28th Annual Global Healthcare Conference
Strong first quarter results and raised guidance reflect robust U.S. segment growth and successful integration of recent acquisitions. Ongoing investments in specialty and MSO strategy, along with a stable outlook for generics and biosimilars, position the business for continued long-term growth.
Cencora Transcript: AGM 2026
The meeting covered director elections, executive compensation, and auditor ratification, all of which passed by majority vote. Financial results showed 16% growth in adjusted operating income and EPS, with new acquisitions and a $1 billion investment commitment announced.
Cencora's animal health unit to merge with Covetrus in $3.5 billion deal
Drug distributor Cencora will merge its MWI Animal Health unit with privately held Covetrus in a deal that values MWI at $3.5 billion, the companies said on Wednesday.